Obesity is a significant public health concern and a growing epidemic in the G7 countries. The body of evidence highlighting the physical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, few drug treatments are available, especially in Europe and Japan. Available treatments have either undesirable risk:benefit profiles or severe payer restrictions. Consequently, there is a huge market opportunity for an antiobesity drug that elicits sustained weight loss and is safe, well tolerated, and affordable. There is a relatively sparse late-phase pipeline for obesity and a promising volume of activity in early phases of development. However, given the prevalence of obesity, even if effective agents reach the market, stringent payer-controlled usage restrictions are likely to be necessary to limit the impact on healthcare budgets.

Questions answered:

  • Which metabolic and central pathways have high potential as drug targets?
  • What is the prevalence of obesity in the major pharmaceutical markets under study?
  • How is obesity currently treated? What do experts think about Novo Nordisk’s Saxenda as a treatment for obese / overweight patients?
  • What is the current level of unmet need according to obesity experts? How will this need be addressed over the 2018-2028 forecast period?
  • What is the commercial potential of Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide? How do leaders in the field of obesity management rate these drug candidates?
  • How will the obesity market evolve over the next ten years?

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Obesity/Overweight - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q3 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q3 2020
        • September 2020
      • Q4 2019
        • November 2019
      • Q3 2019
        • September 2019
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for Obesity / Overweight: 2018
        • Market Share of Drug Classes for Obesity / Overweight: 2028
        • Obesity / Overweight SWOT Analysis
      • COVID-19: Areas of Potential Forecast Impact
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Obesity / Overweight?
          • What Factors Are Constraining the Market for Obesity / Overweight?
          • Patient Share by Drug Classes for Obesity in the Major Markets: 2018-2028
          • Total Obesity Sales by Drug Classes in the Major Markets: 2018-2028
          • Sales by Obese and Drug-Eligible Overweight Subpopulations in the United States: 2018-2028
        • Drug-Class-Specific Trends
          • Patient Share of Saxenda and Semaglutide in the United States: 2018-2028
          • Total Sales of Saxenda and Semaglutide for Obesity in the United States: 2018-2028
          • Patient Share of Saxenda and Semaglutide in the Major European Markets: 2018-2028
          • Total Sales of Saxenda and Semaglutide for Obesity in the Europe: 2018-2028
          • Patient Share and Sales of Semaglutide for Obesity in Japan: 2018-2028
          • Patient Share and Sales of Tirzepatide in the United States: 2018-2028
          • Patient Share and Sales of Tirzepatide in the Major European Markets: 2018-2028
          • Patient Share and Sales of Tirzepatide in Japan: 2018-2028
          • Patient Share and Sales of Qsymia in the United States: 2018-2028
          • Patient Share of Contrave / Mysimba in the Major European Markets: 2018-2028
          • Patient Share and Sales of Contrave / Mysimba in the United States: 2018-2028
          • Total Sales of Contrave / Mysimba in the Major European Markets: 2018-2028
          • Patient Share and Sales of Belviq in the United States: 2018-2028
          • Patient Share of Off-Label Medications for Obesity in the United States: 2018-2028
          • Sales of Off-Label Medications for Obesity in the United States: 2018-2028
          • Patient Share of Off-Label Medications for Obesity in Europe: 2018-2028
          • Sales of Off-Label Medications for Obesity in Europe: 2018-2028
          • Patient Share of Off-Label Medications for Obesity in Japan: 2018-2028
      • Forecast
        • Market Forecast Assumptions - Obesity (2018-2028) - November 2019
        • Market Forecast Dashboard - Obesity (2018-2028) - November 2019
      • Etiology and Pathophysiology
        • Disease Overview
          • Etiology
            • Pathophysiology
              • Natural History
                • Major Complications Related to Obesity
              • Key Pathways and Drug Targets
                • Drug Targets in Obesity: Energy Storage
                • Drug Targets in Obesity: Energy Expenditure
                • Drug Targets in Obesity: Gastrointestinal System
                • Neural and Hormonal Mediators of Hunger and Satiety
                • Drug Targets in Obesity: Central Nervous System
                • Hypothalamic Structures of the Brain Involved in Food Intake Regulation
            • Epidemiology
              • Key Findings
                • Epidemiology Populations
                  • Disease Definition
                  • Methods
                  • Sources Used for the Total Prevalence of Obesity and Overweight
                  • Total Prevalent Cases of Obesity in the Mature Markets (millions): 2018-2028
                  • Total Prevalent Cases of Overweight in the Mature Markets (millions): 2018-2028
                  • Disease Definition
                  • Methods
                  • Sources Used for Obesity Subtypes by Disease Severity
                  • Total Prevalent Cases of Obesity by Disease Severity (millions): 2018-2028
                  • Disease Definition
                  • Methods
                  • Sources Used for Total Prevalence of Drug-Eligible Overweight
                  • Total Prevalent Cases of Drug-Eligible Overweight in the Mature Markets (millions): 2018-2028
                  • Diagnosed Prevalent Cases
                  • Diagnosed Prevalent Cases of Obesity in the Mature Markets (thousands): 2018-2028
                  • Diagnosed Prevalent Cases of Drug-Eligible Overweight in the Mature Markets (thousands): 2018-2028
                  • Drug-Treated Cases of Obesity and Overweight
                  • Drug-Treated Cases of Obesity in the Mature Markets (thousands): 2018-2028
                  • Drug-Treated Cases of Overweight in the Mature Markets (thousands): 2018-2028
              • Current Treatment
                • Key Findings
                  • Treatment Goals
                    • Key Endpoints Used in Clinical Trials for Obesity
                  • Key Current Therapies
                    • Overview
                    • Mechanism of Action of Key Current Drug Classes Used for Obesity
                    • Current Treatments Used for Obesity
                    • Market Events Impacting the Use of Key Current Therapies for Obesity
                    • Advantages and Disadvantages of Saxenda
                    • Expert Insight: Saxenda
                    • Advantages and Disadvantages of Qsymia
                    • Expert Insight: Qsymia
                    • Advantages and Disadvantages of Contrave / Mysimba
                    • Expert Insight: Contrave / Mysimba
                    • Advantages and Disadvantages of Xenical
                    • Expert Insight: Xenical
                    • Advantages and Disadvantages of Phentermine
                    • Expert Insight: Phentermine
                    • Advantages and Disadvantages of Mazindol
                    • Expert Insight: Mazindol
                    • Advantages and Disadvantages of Off-Label Prescription Drugs
                    • Expert Insight: Off-Label Prescription Drugs
                  • Medical Practice
                    • Overview
                    • Country-Specific Obesity Treatment Guidelines
                    • Factors Influencing Drug Selection in Obesity
                    • Treatment Decision Tree for Obesity: United States
                    • Treatment Decision Tree for Obesity: Europe
                    • Treatment Decision Tree for Obesity: Japan
                • Unmet Need Overview
                  • Current and Future Attainment of Unmet Needs in Obesity / Overweight
                  • Top Unmet Needs in Obesity: Current and Future Attainment
                  • Expert Insight: Unmet Need in Obesity / Overweight
                • Emerging Therapies
                  • Key Findings
                    • Key Emerging Therapies
                      • Key Emerging Therapies in Development for Obesity
                      • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Obesity
                      • Semaglutide Profile
                      • Expert Insight: Semaglutide
                      • Expectations for Launch and Sales Opportunity of Semaglutide in Obesity
                      • Tirzepatide Profile
                      • Analysis of the Clinical Development Program for Tirzepatide
                      • Expert Insight: Tirzepatide
                      • Expectations for Launch and Sales Opportunity of Tirzepatide in Obesity
                      • Select Phase III Niche Obesity Disorder Compounds
                    • Early-Phase Pipeline Analysis
                      • Select Compounds in Early-Phase Development for Obesity / Overweight
                    • Key Discontinuations and Failures in Obesity / Overweight
                      • Key Discontinuations and Failures
                  • Access & Reimbursement Overview
                    • Region-Specific Reimbursement Practices
                      • Key Market Access Considerations in Obesity: United States
                      • General Reimbursement Environment: United States
                      • Key Market Access Considerations in Obesity: EU5
                      • General Reimbursement Environment: EU5
                      • Key Market Access Considerations in Obesity: Japan
                      • General Reimbursement Environment: Japan
                    • Looking for More?
                  • Appendix
                    • Obesity Bibliography

                Author(s): Tej Pal, M.Pharm.

                Tej Pal, M.Pharm., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. Previously, he was an analyst at IQVIA and at Smart Analyst Inc., where he worked closely with top pharmaceutical companies on commercial and technical ad-hoc requests. During his tenure there, he delivered competitive landscape and market insight projects on various oncology indications. He holds a master’s degree in pharmacy with a specialization in pharmaceutical chemistry from the Delhi Institute of Pharmaceutical Sciences and Research in New Delhi, India.


                Related Reports

                Obesity/Overweight - Current Treatment - Obesity | Treatment Algorithms: Claims Data Analysis | US | Dashboard

                Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic phentermin...

                View Details

                Obesity/Overweight | Treatment Algorithms: Claims Data Analysis | US | 2020

                Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic phentermin...

                View Details

                Obesity/Overweight - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis -2020

                Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic phentermin...

                View Details